Inotiv Expands Protein/Peptide Bioanalytical Capabilities With This Deal

Vandana Singh
1 min read
0
In this article:

  • Contract research organization Inotiv Inc (NASDAQ: NOTV) acquired Nashville, Tennessee-based Protypia Inc for $11 million.

  • Inotiv specializes in nonclinical and analytical drug discovery, development services, research models, and related products and services.

  • Protypia is a protein/peptide bioanalytical company offering high-quality, targeted tissue-based protein and peptide mass spectrometry.

  • Deal consideration consists of approximately $9.5 million in cash, Inotiv common shares of approximately $0.9 million, and $0.6 million in unsecured subordinated promissory notes.

  • The company expects to retain all existing Protypia employees and maintain operations in Nashville.

  • "This highly-specialized technology and know-how significantly enhances our ability to support clients in developing safe and effective medicines, particularly in the areas of immuno-oncology and cell and gene therapy. The ability to precisely quantify protein levels in tissues, including paraffin-embedded tissues, opens exciting new avenues for scientists to explore as they investigate disease pathways," said John Sagartz, Inotiv's Chief Strategy Officer.

  • Price Action: NOTV shares closed 2.53% higher at $10.94 on Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories